Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SESIFAL: Additional effect of SGLT-2 inhibitor on liver fat in type 2 diabetes with hepatic steatosis
jRCTs031200093Completed
- Sponsor
- Taisho Pharmaceutical
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of luseogliflozin in type 2 diabetes mellitus (T2DM) and steatosis (2 arms), sponsored by Taisho Pharmaceutical. Primary endpoint: Change in liver proton density fat fraction (PDFF) by MRI. Started Aug 2021; status: completed.
02
Drugs
luseogliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)steatosis
Beyond the preview
Go deeper on jRCTs031200093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031200093.